The investigators sought to determine whether TNF-α and adiponectin levels might play a role in differentiating psoriatic arthritis from psoriasis.
Although patients with CCLE responded well, the numbers were small and additional research with respect to this finding is warranted.
Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.
A majority of the physician participants reported that CLASI was an easier tool to use compared with PGA.
The risk for depression was increased significantly in patients with systemic lupus erythematosus and cutaneous lupus erythematosus.
Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.
The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.
Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.
The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.
Weekly belimumab is associated with greater benefit than placebo for patients with hypocomplementemic/anti-double stranded (ds)DNA-positive systemic lupus erythematosus.